Abstract
31 patients with multiple sclerosis were treated for an mean period of 4 years with high doses of human immunoglobulin. Overall, one third improved, one third showed no change and one third deteriorated. The effect of treatment was not related to any clinical or biological variable except perhaps the immunogenetic profile (HLA). The potential role of this symptomatic treatment is discussed.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Complement System Proteins / analysis
-
Female
-
HLA Antigens / analysis
-
Humans
-
Immunoglobulin G / administration & dosage*
-
Immunoglobulins / analysis
-
Male
-
Middle Aged
-
Multiple Sclerosis / diagnosis
-
Multiple Sclerosis / immunology
-
Multiple Sclerosis / therapy*
Substances
-
HLA Antigens
-
Immunoglobulin G
-
Immunoglobulins
-
Complement System Proteins